Intensive Care Medicine

, Volume 27, Issue 1, pp 115–121 | Cite as

Pharmacokinetics of sequential intravenous and enteral fluconazole in critically ill surgical patients with invasive mycoses and compromised gastro-intestinal function

  • S.L.C.E. Buijk
  • I.C. Gyssens
  • J.W. Mouton
  • H.A. Verbrugh
  • D.J. Touw
  • H.A. Bruining
Original

Abstract

Objectives: (1) To determine the pharmacokinetics of sequential intravenous and enteral fluconazole in the serum of surgical intensive care unit (ICU) patients with deep mycoses. (2) To determine the concentrations of fluconazole reached at the site of infection. (3) To determine if enteral administration of fluconazole, which has an important pharmaco-economic advantage, is justified in this specific patient group. Design: Descriptive, sequential study as a part of a therapeutic drug monitoring programme. Setting: Eighteen-bed surgical ICU in a referral centre. Patients: Fourteen critically ill surgical patients with recent gastro-intestinal (GI) surgery and deep mycosis caused by a fluconazole-susceptible fungus and a calculated creatinine clearance of more than 40 ml/min. Interventions: Fluconazole dosage regimen: 400 mg i.v. every 24 h with an extra dose of 400 mg i.v. after 12 h on day 1. If the clinical condition allowed enteral administration on day 4, the content of two capsules of 200 mg was given via the feeding tube with concomitant enteral feeds. Measurements and main results: Serum, exudate from the site of infection and urine samples collected at assumed steady state ( after ≥5 doses). Fluconazole concentrations were determined by high-performance liquid chromatography (HPLC). The mean area under the concentration curve (AUC0–24 h) in serum after enteral administration did not significantly differ from the AUC0–24 h during intravenous treatment. The elimination half-life was longer compared to healthy volunteers. The mean (95% CI) estimated bioavailability was 124 (90–158)%. The mean (95% CI) area under the concentration time curves (AUCs) achieved in the exudate from the site of infection were 67 (55–79)% of the AUCs reached in serum for both regimens. Conclusions: In critically ill patients with recent GI surgery and/or peritonitis the bioavailability of enteral fluconazole was adequate. The concentrations of fluconazole reached in exudate were lower than those in serum for both regimens, but adequate to treat most cases of deep mycoses in this specific patient group.

Fluconazole Pharmacokinetics Critically ill Deep mycoses Compromised gastro-intestinal function 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag 2000

Authors and Affiliations

  • S.L.C.E. Buijk
    • 1
  • I.C. Gyssens
    • 2
  • J.W. Mouton
    • 2
  • H.A. Verbrugh
    • 2
  • D.J. Touw
    • 3
  • H.A. Bruining
    • 1
  1. 1.Department of Surgical Intensive Care, Erasmus University Medical Center Rotterdam, P.O. Box 2040, 3000 CA Rotterdam, The NetherlandsThe Netherlands
  2. 2.Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center Rotterdam, P.O. Box 2040, 3000 CA Rotterdam, The NetherlandsThe Netherlands
  3. 3.Department of Pharmacy, Academic Hospital Vrije Universiteit, De Boelelaan 1117, 1081 HV Amsterdam, The NetherlandsThe Netherlands
  4. 4.Address for correspondence: Department of Surgery, Reinier de Graaf Gasthuis, Reinier de Graafweg 11, 2625 AD Delft, The NetherlandsThe Netherlands

Personalised recommendations